Loading…
Interaction of Caffeine With Regadenoson-Induced Hyperemic Myocardial Blood Flow as Measured by Positron Emission Tomography: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
[...]it seems that caffeine blunts the vasodilatory effect of adenosine but has a limited effect on regadenoson. The interaction of caffeine with adenosine-induced, dipyridamole-induced, and even exercise-induced MBF changes (4,6) may limit the correct detection of coronary artery disease and subseq...
Saved in:
| Published in: | Journal of the American College of Cardiology 2008-01, Vol.51 (3), p.328-329 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 329 |
| container_issue | 3 |
| container_start_page | 328 |
| container_title | Journal of the American College of Cardiology |
| container_volume | 51 |
| creator | Gaemperli, Oliver Schepis, Tiziano Koepfli, Pascal Siegrist, Patrick T. Fleischman, Samuel Nguyen, Patricia Olmsted, Ann Wang, Whedy Lieu, Hsiao Kaufmann, Philipp A. |
| description | [...]it seems that caffeine blunts the vasodilatory effect of adenosine but has a limited effect on regadenoson. The interaction of caffeine with adenosine-induced, dipyridamole-induced, and even exercise-induced MBF changes (4,6) may limit the correct detection of coronary artery disease and subsequently the proper management of the patient, leading to the general recommendation to withhold caffeine for 24 h before vasodilator stress testing (3). Because the hyperemic MBF response to regadenoson after caffeine administration lies well within the range of reported response to nonselective adenosine receptor agonists and bicycle stress (6), the present study suggests that regadenoson causes coronary hyperemia with and without prior caffeine ingestion in healthy volunteers and moderate caffeine consumption may not interfere with regadenoson stress MPI. |
| doi_str_mv | 10.1016/j.jacc.2007.10.014 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_1506197386</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0735109707034377</els_id><sourcerecordid>3242918801</sourcerecordid><originalsourceid>FETCH-LOGICAL-e205t-2bdbfd230264a1b4a1abc26be473083845e3fcb28f206282f9678f6d87a640de3</originalsourceid><addsrcrecordid>eNo1kc1u1DAUhS0EokPhBVggS2zJYDuJkyA2bejPSK2oqkEsLf_ctI4Se2onReHZeLg6allcWffq0znWOQh9pGRLCeVf-20vtd4yQqp02BJavEIbWpZ1lpdN9RptSJWXGSVNdYTexdgTQnhNm7foiNaM8KooNujfzk0QpJ6sd9h3uJVdB9YB_m2ne3wLd9KA89G7bOfMrMHgy-UAAUar8fXitQzGygGfDt4bfD74P1hGfA0yziGxasE3PtopJPGz0ca4uuz96O-CPNwv3_AJvpXO-NH-BfMF__CzGiA7HaxL280gNSiftd4lgWFIem3wMfpHCHgfku179KaTQ4QPL-8x-nV-tm8vs6ufF7v25CoDRsopY8qozrCcMF5IqtJIpRlXUFQ5qfO6KCHvtGJ1l1JhNesaXtUdN3UleUEM5Mfo87PuIfiHGeIkej8HlywFLQmnTZXXPFGfXqhZjWDEIdhRhkX8DzsB358BSH99tBBE1BZcCtUG0JMw3gpKxNqt6MXarVi7XW-p2_wJ6cCZRw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1506197386</pqid></control><display><type>article</type><title>Interaction of Caffeine With Regadenoson-Induced Hyperemic Myocardial Blood Flow as Measured by Positron Emission Tomography: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial</title><source>BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS</source><creator>Gaemperli, Oliver ; Schepis, Tiziano ; Koepfli, Pascal ; Siegrist, Patrick T. ; Fleischman, Samuel ; Nguyen, Patricia ; Olmsted, Ann ; Wang, Whedy ; Lieu, Hsiao ; Kaufmann, Philipp A.</creator><creatorcontrib>Gaemperli, Oliver ; Schepis, Tiziano ; Koepfli, Pascal ; Siegrist, Patrick T. ; Fleischman, Samuel ; Nguyen, Patricia ; Olmsted, Ann ; Wang, Whedy ; Lieu, Hsiao ; Kaufmann, Philipp A.</creatorcontrib><description>[...]it seems that caffeine blunts the vasodilatory effect of adenosine but has a limited effect on regadenoson. The interaction of caffeine with adenosine-induced, dipyridamole-induced, and even exercise-induced MBF changes (4,6) may limit the correct detection of coronary artery disease and subsequently the proper management of the patient, leading to the general recommendation to withhold caffeine for 24 h before vasodilator stress testing (3). Because the hyperemic MBF response to regadenoson after caffeine administration lies well within the range of reported response to nonselective adenosine receptor agonists and bicycle stress (6), the present study suggests that regadenoson causes coronary hyperemia with and without prior caffeine ingestion in healthy volunteers and moderate caffeine consumption may not interfere with regadenoson stress MPI.</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/j.jacc.2007.10.014</identifier><identifier>PMID: 18206744</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adenosine A2 Receptor Agonists ; Adenosine A2 Receptor Antagonists ; Blood pressure ; Caffeine - pharmacology ; Cardiology ; Cardiovascular disease ; Coronary Circulation - drug effects ; Coronary vessels ; Cross-Over Studies ; Double-Blind Method ; Drug Interactions ; Heart Rate - drug effects ; Humans ; Medical research ; Positron-Emission Tomography ; Purines - pharmacology ; Pyrazoles - pharmacology ; Tomography ; Vasodilator Agents - pharmacology</subject><ispartof>Journal of the American College of Cardiology, 2008-01, Vol.51 (3), p.328-329</ispartof><rights>2008 American College of Cardiology Foundation</rights><rights>Copyright Elsevier Limited Jan 22, 2008</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18206744$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gaemperli, Oliver</creatorcontrib><creatorcontrib>Schepis, Tiziano</creatorcontrib><creatorcontrib>Koepfli, Pascal</creatorcontrib><creatorcontrib>Siegrist, Patrick T.</creatorcontrib><creatorcontrib>Fleischman, Samuel</creatorcontrib><creatorcontrib>Nguyen, Patricia</creatorcontrib><creatorcontrib>Olmsted, Ann</creatorcontrib><creatorcontrib>Wang, Whedy</creatorcontrib><creatorcontrib>Lieu, Hsiao</creatorcontrib><creatorcontrib>Kaufmann, Philipp A.</creatorcontrib><title>Interaction of Caffeine With Regadenoson-Induced Hyperemic Myocardial Blood Flow as Measured by Positron Emission Tomography: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial</title><title>Journal of the American College of Cardiology</title><addtitle>J Am Coll Cardiol</addtitle><description>[...]it seems that caffeine blunts the vasodilatory effect of adenosine but has a limited effect on regadenoson. The interaction of caffeine with adenosine-induced, dipyridamole-induced, and even exercise-induced MBF changes (4,6) may limit the correct detection of coronary artery disease and subsequently the proper management of the patient, leading to the general recommendation to withhold caffeine for 24 h before vasodilator stress testing (3). Because the hyperemic MBF response to regadenoson after caffeine administration lies well within the range of reported response to nonselective adenosine receptor agonists and bicycle stress (6), the present study suggests that regadenoson causes coronary hyperemia with and without prior caffeine ingestion in healthy volunteers and moderate caffeine consumption may not interfere with regadenoson stress MPI.</description><subject>Adenosine A2 Receptor Agonists</subject><subject>Adenosine A2 Receptor Antagonists</subject><subject>Blood pressure</subject><subject>Caffeine - pharmacology</subject><subject>Cardiology</subject><subject>Cardiovascular disease</subject><subject>Coronary Circulation - drug effects</subject><subject>Coronary vessels</subject><subject>Cross-Over Studies</subject><subject>Double-Blind Method</subject><subject>Drug Interactions</subject><subject>Heart Rate - drug effects</subject><subject>Humans</subject><subject>Medical research</subject><subject>Positron-Emission Tomography</subject><subject>Purines - pharmacology</subject><subject>Pyrazoles - pharmacology</subject><subject>Tomography</subject><subject>Vasodilator Agents - pharmacology</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNo1kc1u1DAUhS0EokPhBVggS2zJYDuJkyA2bejPSK2oqkEsLf_ctI4Se2onReHZeLg6allcWffq0znWOQh9pGRLCeVf-20vtd4yQqp02BJavEIbWpZ1lpdN9RptSJWXGSVNdYTexdgTQnhNm7foiNaM8KooNujfzk0QpJ6sd9h3uJVdB9YB_m2ne3wLd9KA89G7bOfMrMHgy-UAAUar8fXitQzGygGfDt4bfD74P1hGfA0yziGxasE3PtopJPGz0ca4uuz96O-CPNwv3_AJvpXO-NH-BfMF__CzGiA7HaxL280gNSiftd4lgWFIem3wMfpHCHgfku179KaTQ4QPL-8x-nV-tm8vs6ufF7v25CoDRsopY8qozrCcMF5IqtJIpRlXUFQ5qfO6KCHvtGJ1l1JhNesaXtUdN3UleUEM5Mfo87PuIfiHGeIkej8HlywFLQmnTZXXPFGfXqhZjWDEIdhRhkX8DzsB358BSH99tBBE1BZcCtUG0JMw3gpKxNqt6MXarVi7XW-p2_wJ6cCZRw</recordid><startdate>20080122</startdate><enddate>20080122</enddate><creator>Gaemperli, Oliver</creator><creator>Schepis, Tiziano</creator><creator>Koepfli, Pascal</creator><creator>Siegrist, Patrick T.</creator><creator>Fleischman, Samuel</creator><creator>Nguyen, Patricia</creator><creator>Olmsted, Ann</creator><creator>Wang, Whedy</creator><creator>Lieu, Hsiao</creator><creator>Kaufmann, Philipp A.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20080122</creationdate><title>Interaction of Caffeine With Regadenoson-Induced Hyperemic Myocardial Blood Flow as Measured by Positron Emission Tomography: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial</title><author>Gaemperli, Oliver ; Schepis, Tiziano ; Koepfli, Pascal ; Siegrist, Patrick T. ; Fleischman, Samuel ; Nguyen, Patricia ; Olmsted, Ann ; Wang, Whedy ; Lieu, Hsiao ; Kaufmann, Philipp A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e205t-2bdbfd230264a1b4a1abc26be473083845e3fcb28f206282f9678f6d87a640de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adenosine A2 Receptor Agonists</topic><topic>Adenosine A2 Receptor Antagonists</topic><topic>Blood pressure</topic><topic>Caffeine - pharmacology</topic><topic>Cardiology</topic><topic>Cardiovascular disease</topic><topic>Coronary Circulation - drug effects</topic><topic>Coronary vessels</topic><topic>Cross-Over Studies</topic><topic>Double-Blind Method</topic><topic>Drug Interactions</topic><topic>Heart Rate - drug effects</topic><topic>Humans</topic><topic>Medical research</topic><topic>Positron-Emission Tomography</topic><topic>Purines - pharmacology</topic><topic>Pyrazoles - pharmacology</topic><topic>Tomography</topic><topic>Vasodilator Agents - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gaemperli, Oliver</creatorcontrib><creatorcontrib>Schepis, Tiziano</creatorcontrib><creatorcontrib>Koepfli, Pascal</creatorcontrib><creatorcontrib>Siegrist, Patrick T.</creatorcontrib><creatorcontrib>Fleischman, Samuel</creatorcontrib><creatorcontrib>Nguyen, Patricia</creatorcontrib><creatorcontrib>Olmsted, Ann</creatorcontrib><creatorcontrib>Wang, Whedy</creatorcontrib><creatorcontrib>Lieu, Hsiao</creatorcontrib><creatorcontrib>Kaufmann, Philipp A.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gaemperli, Oliver</au><au>Schepis, Tiziano</au><au>Koepfli, Pascal</au><au>Siegrist, Patrick T.</au><au>Fleischman, Samuel</au><au>Nguyen, Patricia</au><au>Olmsted, Ann</au><au>Wang, Whedy</au><au>Lieu, Hsiao</au><au>Kaufmann, Philipp A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interaction of Caffeine With Regadenoson-Induced Hyperemic Myocardial Blood Flow as Measured by Positron Emission Tomography: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial</atitle><jtitle>Journal of the American College of Cardiology</jtitle><addtitle>J Am Coll Cardiol</addtitle><date>2008-01-22</date><risdate>2008</risdate><volume>51</volume><issue>3</issue><spage>328</spage><epage>329</epage><pages>328-329</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><abstract>[...]it seems that caffeine blunts the vasodilatory effect of adenosine but has a limited effect on regadenoson. The interaction of caffeine with adenosine-induced, dipyridamole-induced, and even exercise-induced MBF changes (4,6) may limit the correct detection of coronary artery disease and subsequently the proper management of the patient, leading to the general recommendation to withhold caffeine for 24 h before vasodilator stress testing (3). Because the hyperemic MBF response to regadenoson after caffeine administration lies well within the range of reported response to nonselective adenosine receptor agonists and bicycle stress (6), the present study suggests that regadenoson causes coronary hyperemia with and without prior caffeine ingestion in healthy volunteers and moderate caffeine consumption may not interfere with regadenoson stress MPI.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>18206744</pmid><doi>10.1016/j.jacc.2007.10.014</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0735-1097 |
| ispartof | Journal of the American College of Cardiology, 2008-01, Vol.51 (3), p.328-329 |
| issn | 0735-1097 1558-3597 |
| language | eng |
| recordid | cdi_proquest_journals_1506197386 |
| source | BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS |
| subjects | Adenosine A2 Receptor Agonists Adenosine A2 Receptor Antagonists Blood pressure Caffeine - pharmacology Cardiology Cardiovascular disease Coronary Circulation - drug effects Coronary vessels Cross-Over Studies Double-Blind Method Drug Interactions Heart Rate - drug effects Humans Medical research Positron-Emission Tomography Purines - pharmacology Pyrazoles - pharmacology Tomography Vasodilator Agents - pharmacology |
| title | Interaction of Caffeine With Regadenoson-Induced Hyperemic Myocardial Blood Flow as Measured by Positron Emission Tomography: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T13%3A45%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interaction%20of%20Caffeine%20With%20Regadenoson-Induced%20Hyperemic%20Myocardial%20Blood%20Flow%20as%20Measured%20by%20Positron%20Emission%20Tomography:%20A%20Randomized,%20Double-Blind,%20Placebo-Controlled%20Crossover%20Trial&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=Gaemperli,%20Oliver&rft.date=2008-01-22&rft.volume=51&rft.issue=3&rft.spage=328&rft.epage=329&rft.pages=328-329&rft.issn=0735-1097&rft.eissn=1558-3597&rft_id=info:doi/10.1016/j.jacc.2007.10.014&rft_dat=%3Cproquest_pubme%3E3242918801%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-e205t-2bdbfd230264a1b4a1abc26be473083845e3fcb28f206282f9678f6d87a640de3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1506197386&rft_id=info:pmid/18206744&rfr_iscdi=true |